Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
AP-SA02
/
Armata
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
AP-SA02
/
Armata
Phase classification, Trial completion date, Trial primary completion date:
diSArm: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
(clinicaltrials.gov) - Dec 12, 2023
P1/2
, N=50, Recruiting,
Sponsor: Armata Pharmaceuticals, Inc.
Phase classification: P1b/2a --> P1/2 | Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Sep 2023 --> Dec 2024
||
||||||||
AP-SA02
/
Armata
Enrollment open:
diSArm: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
(clinicaltrials.gov) - May 1, 2022
P1b/2a
, N=50, Recruiting,
Sponsor: Armata Pharmaceuticals, Inc.
Phase classification: P1b/2a --> P1/2 | Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Sep 2023 --> Dec 2024 Not yet recruiting --> Recruiting